in experimental animals (Park et al., 1995; Inoue et al., 2000; Wakeling et al., 2002; Pollack et al., 1999) and in human clinical trials (Baselga et al., 1998; Cunningham et al., 2004; DiMaio et al., 2005) .
Because ErbB2 can transactivate other ErbB receptors and is the preferred heterodimerization partner among all the ErbB receptors (Olayioye et al., 1998) , simultaneous suppression of ErbB2 and EGFR may provide superior inhibition of signaling driving tumor proliferation. Indeed, a combination of EGFR and ErbB2 kinase inhibitors was shown to be more effective at inhibiting proliferation and inducing apoptosis over either agent alone (Zhou et al., 2006) . This strategy is reflected in the development of lapatinib (GW572016, Tykerb®), a small molecule kinase inhibitor of EGFR and ErbB2 that has shown promising activity in the clinic and was recently approved for use in combination with capecitabine for the treatment of ErbB2 overexpressing advanced or metastatic breast cancer after prior therapy with an anthracycline, a taxane and trastuzumab (Moy et al., 2007) .
ErbB2 overexpressing tumors have a greater incidence of CNS metastasis possibly resulting from an enhanced metastatic potential (Yu et al., 1994) . In addition, the success of trastuzumab has increased the survival of patients with ErbB2 positive breast cancer and created a larger patient population where brain metastases have time to develop due to an increased life span and the inability of trastuzumab to penetrate the blood brain barrier (Clayton et al., 2004) . Following diagnosis of metastatic lesions in the brain, less than 20% of patients survive for more than one year and less than 2% survive for 2 years or longer (Shaffrey et al., 2004) . JNJ-28871063 is a potent inhibitor of the EGFR, ErbB2 and ErbB4 receptor kinases and showed efficacy against EGFR and ErbB2-dependent tumor xenografts. Furthermore, this compound crosses the blood-brain barrier and showed activity in an ErbB2 overexpressing brain tumor model. Because few effective treatment options exist for ErbB overexpressing tumors that have metastasized to the brain, these results support further development of JNJ-28871063 to determine if it will provide therapeutic benefit for these cases.
This article has not been copyedited and formatted. The final version may differ from this version. values were calculated with standard deviation from 2-8 separate experiments. Assays for inhibition of CDK1, CDK2, insulin receptor kinaseβ, PDGF-Rβ kinase and VEGF-R2 kinase were performed as described (Emanuel et al., 2004) . Kinase selectivity profiling was carried out at Upstate Biotechnology (Lake Placid, NY) and Invitrogen Corporation (Carlsbad, CA). Upstate Biotechnology, Lake Placid, NY) to determine the extent of phosphorylation of the immobilized ErbB2 receptor. A similar strategy using the same capture plate but substituting a different antiphosphotyrosine detection antibody has been described previously (Barbacci et al., 2003 Cell Proliferation Assays. Antiproliferative activity of ErbB kinase inhibitors was assessed in monolayer cultures of cells in logarithmic growth by 14 C-thymidine incorporation into cellular DNA as described (Emanuel et al., 2004) except that total time that cells were exposed to drug was 96 hours. 
Measurement of ErbB Tyrosine Phosphorylation in Cells and

Tumor Xenograft
RESULTS
Inhibition of ErbB Kinase Activity
In Vitro. JNJ-28871063 (Fig. 1A) represents a novel class of aminopyrimidine oxime kinase inhibitor that has structural overlap with the aminoquinazoline pharmacophore known to inhibit various biologically relevant kinases. IC 50 values of 22, 38 and 21 nM, respectively, were obtained for inhibition of the ErbB1, ErbB2 and ErbB4 isoforms. In these in vitro kinase assays, JNJ-28871063 exhibits a broader ErbB inhibitory profile than the comparator compounds gefitinib and erlotinib, which are focused primarily on ErbB1 inhibition, and has pan-Erb inhibitory activity similar to lapatinib ( Table 1 In Vitro Kinase Selectivity Profile. To characterize the selectivity of inhibition, compounds were tested in duplicate at a single concentration of 1 or 3 µM for activity against a representative panel of 210 tyrosine and serine/threonine kinases in the presence of 10 µM ATP (Upstate Biotechnology, Lake Placid, NY, and Invitrogen Corporation, Carlsbad, CA). The percent inhibition of control is presented as a heat map in Figure 1D . Lapatanib was the most selective inhibitor with 2 off target kinases inhibited between 50% and 80% and 2 off target kinases inhibited greater than 80%. JNJ-28871063 inhibited 6 off target kinases between 50% and 80% and 1 off target kinase greater than 80%. Gefitinib and erlotinib were less selective with 24 off target kinases inhibited greater than 50% and 12 off target kinases inhibited greater than 80%. The specific off target kinases inhibited greater than 80%
are listed in the legend to Figure 1 . (Table 2) . JNJ-28871063 also inhibited growth of the EGFR overexpressing cell line A431
JNJ-28871063 Inhibits Proliferation of ErbB
in the same range as other EGFR kinase inhibitors but was less potent on the HN5 line than the other inhibitors.
JNJ-28871063 and lapatinib showed greater inhibition of ErbB2 overexpressing cell lines than gefitinib and erlotinib
This article has not been copyedited and formatted. The final version may differ from this version. and EGFR in all cell lines were confirmed by immunoblotting (data not shown).
Inhibition of ErbB Phosphorylation in Cells.
To determine if JNJ-28871063 or comparator compounds were able to penetrate into cells and reduce phosphorylation levels of the ErbB2 receptor, a sandwich ELISA was developed in a 96-well format. JNJ-28871063 was able to reduce the basal level of ErbB2 phosphorylation in SKBR3 cells indicating that the compound effectively reaches its intracellular target and interferes with activation of the ErbB2 receptor. In this assay, JNJ-28871063 and lapatinib were 19 ± 3 and 135 ± 4-fold more potent, respectively, than gefitinib in blocking total ErbB2 receptor phosphorylation in SKBR3 cells while erlotinib showed no effect on ErbB2 phosphorylation (Table 1 ). An ELISA assay was also developed to measure the ability of compounds to block EGF-stimulated EGFR phosphorylation in the A431 cell line. JNJ-28871063 and lapatinib were both able to potently inhibit ligand induced EGFR phosphorylation in EGFR overexpressing cells but were less effective than gefitinib and erlotinib (Table 1) . total ERK blots is probably a non-specific band that was observed in all samples in this cell line. JNJ-28871063, lapatinib and gefitinib inhibited phosphorylation of AKT on S473 and phospholipase-C gamma (PLCγ) on Y783
ErbB Receptor Phosphorylation and
while erlotinib showed some reduction of phosphorylation on these proteins but was less effective. In the EGFR overexpressing cell line A431, lapatinib and gefitinib were equally effective at blocking EGF-stimulated phosphorylation of the EGFR on Y845, Y1068, Y1148 and Y1173. JNJ-28871063 and erlotinib were also equipotent but less effective than lapatinib and gefitinib at inhibiting phosphorylation on these residues. All compounds reduced EGFR phosphorylation on Y992 to basal (unstimulated) levels, however, this residue remained highly phosphorylated even after starvation and very little induction was achieved following EGF treatment. All compounds reduced AKT phosphorylation on AKT S473 to unstimulated levels while only gefitinib significantly reduced MAPK phosphorylation. The effects on MAPK activation observed in the immunoblots resulted from a 16-hour exposure to compound and do not parallel the growth inhibition obtained from a 96-hour treatment period seen in the A431 cell proliferation assays (Table 2) .
JNJ-28871063 Penetrates Tumors and Crosses the Blood Brain Barrier. The tissue distribution of JNJ-
28871063 and lapatinib was examined in nude mice bearing A431 tumor xenografts by measuring the amount of drug present in plasma, tumor and brain after a single oral dose of 100 mg/kg. The 1 and 2 hour timepoint were selected for analysis of drug levels in the brain because preliminary pharmacokinetic studies showed that peak drug plasma levels were present at 1 hour after po dosing for JNJ-28871063 and lapatinib in both mice and rats. After 1 hour, both JNJ-28871063 and lapatinib produced micromolar drug plasma concentrations. JNJ-28871063 accumulated to slightly higher drug levels in tumors than found in plasma while there were lower levels of lapatinib in tumors than found in plasma. JNJ-28871063 penetrated into the brain and was present at concentrations double those found in plasma whereas lapatinib showed very little penetration into the brain (Figure 3 ). Drug concentrations were also measured in this experiment after 2 hours and brain/tumor/plasma drug levels were all slightly lower than at 1 hour but the trend was the same as that seen at the 1 hour timepoint (data not shown). In a separate experiment drug levels in plasma and tumor were measured in mice bearing N87 xenografts and JNJ-28871063 accumulated to higher levels in tumor tissue (data not shown). After single-dose i.v. administration in rats, JNJ-28871063 was also able to penetrate into the brain and accumulate to 2.5-fold higher levels than present in plasma while the ability of lapatinib to penetrate into the brain was extremely low (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. Inhibition of Human Tumor Xenograft Growth. The anti-tumor activity of JNJ-28871063 was evaluated in several human tumor xenograft models. Prior to initiating treatment, tumors were implanted and allowed to establish growth for 7 to 14 days. Results of these studies are summarized in Table 3 for the various tumor types.
The N87 gastric carcinoma overexpresses ErbB2 as a result of gene amplification (Kasprzyk et al., 1992) . In both N87 models, JNJ-28871063 was formulated as a suspension in 0.5% methylcellulose and administered p.o at 100 mg/kg on a QD X 30 schedule. In the first N87 model, trastuzumab was reconstituted in PBS as recommended by the manufacturer and administered i.p at 20 mg/kg twice a week for four weeks. JNJ-28871063 showed significant inhibition of tumor growth (TGI = 71%, p = 0.006) while trastuzumab showed slight but not significant inhibition of tumor growth (TGI = 11.4%, p = 0.486) ( Figure 4A and Table 3 ). In a second N87 model, JNJ-28871063 again showed a significant TGI of 69.4% (p = 0.003); lapatinib (Tykerb®, GSK572016; GlaxoSmithKline) also resulted in significant tumor inhibition (TGI = 70.1%, p = 0.029) while gefitinib (Iressa®, ZD1839; AstraZeneca) did not significantly inhibit tumor growth ( Figure 4B and Table 3 ). JNJ-28871063 was also evaluated in an A431 human tumor xenograft model to assess its inhibitory effects on EGFR overexpressing tumor growth. The A431 epidermoid carcinoma exhibits gene amplification for the EGFR and in this cell line, EGFR activates signaling pathways responsible for driving proliferation, invasion, and survival of cancer cells (Kawamoto et al., 1983) . JNJ-28871063 was formulated as a suspension in 0.5% methylcellulose and administered p.o. at 100 mg/kg on a QD X 30 schedule. Gefitinib and lapatinib were used as comparators in this study and were prepared and dosed p.o. at 100 mg/kg in the same vehicle and on the same schedule as JNJ-28871063. The experiment started dosing on Day 10 (10 days after tumor inoculation) and was terminated on Day 35. Inhibition of tumor growth is shown graphically in Figure 4C and the summary of the TGI values and percent body weight loss for this study are presented in Table 3 .
JNJ-28871063 produced a significant inhibition of tumor growth at 100 mg/kg (TGI = 66.8%; p = 0.025). Gefitinib caused regression of established tumors and completely inhibited tumor growth at 100 mg/kg (TGI = 94.5%; p = 0.002). Lapatinib resulted in a 9.4% TGI which was not significant (p = 0.596). All groups experienced a net weight gain over the course of the study and no treatment related deaths were recorded in any group. JNJ-28871063
was evaluated in an estrogen dependent BT474 human breast carcinoma tumor xenograft model in CB.17 SCID mice. Trastuzumab was formulated as above and administered i.p. at 12.5 mg/kg twice a week for four weeks. JNJ-28871063 and lapatinib were formulated in 0.5% methylcellulose as suspensions and administered p.o. on a BID X This article has not been copyedited and formatted. The final version may differ from this version. Figure 4D and Table 3 ).
HER2 Pharmacodynamic Assay.
A pharmacodynamic assay was utilized to assess the effects of drug treatments on ErbB2 phosphorylation levels in athymic mice bearing N87 tumor xenografts. Mice were implanted with N87 tumors which were allowed to establish to a size of 300 -600 mg. A single oral dose of JNJ-28871063 was administered p.o., tumors were excised at various times after dosing, and equal amounts of protein were evaluated in the ErbB2 phosphorylation ELISA. JNJ-28871063 significantly reduced the phosphorylation level of ErbB2 in nude mice bearing N87 human tumor xenografts following oral administration. Maximal reduction of ErbB2 phosphorylation (63.1%) was observed in the tumors sampled 1 hour after administration of 100mg/kg compound but a reduction of 44.9% in ErbB2 phosphorylation was still apparent 4 hours after dosing ( Figure 4E ). were at least 10-fold more potent inhibitors of ErbB2 overexpressing cell growth than the EGFR targeted compound erlotinib and were also more potent than gefitinib, which showed some activity towards slowing ErbB2 overexpressing cell proliferation. All compounds were in the same potency range for slowing EGFR overexpressing cell growth and reducing EGF-stimulated EGFR phosphorylation in the A431 cell line, but JNJ-28871063 was 10-fold less efficacious than the comparators at inhibiting growth of the HN5 cell line. This difference cannot be explained by potency against EGFR kinase alone and may be due to genetic factors unique to the HN5 cell line.
Efficacy in an ErbB2
Treatment of ErbB overexpressing cells with tyrosine kinase inhibitors that block ErbB phosphorylation prevents
growth by enhancing internalization, ubiquitination and proteasomal degradation of the receptor (Citri et al., 2002) .
Growth inhibition was specific for cells overexpressing ErbB receptors since greater than 14-fold higher concentrations of JNJ-28871063 failed to inhibit the growth of cells that do not overexpress ErbB2 or EGFR. JNJ-28871063 was the most specific for ErbB overexpressing cells and showed no antiproliferative effects at the highest concentration tested on cell types not dependent on ErbB signaling for growth. In a pharmacodynamic assay with animals bearing ErbB2 overexpressing tumors, a single dose of JNJ-28871063 was able to reduce the level of ErbB2 phosphorylation in the tumors for more than 4 hours after dosing. The cellular activity in EGFR and ErbB2 overexpressing tumor lines revealed distinct profiles of activity for the EGFR and pan-ErbB targeted compounds.
Both JNJ-28871063 and lapatinib equally inhibited phosphorylation of the ErbB2 receptor in BT474 breast carcinoma cells on tyrosine residues responsible for activating downstream growth pathways at the single This article has not been copyedited and formatted. The final version may differ from this version. concentration examined (3 µM). In ErbB2 overexpressing BT474 cells, JNJ-28871063 and lapatinib strongly inhibited the Y1221 and Y1248 residues that are the major autophosphorylation sites on ErbB2 and activate the MAPK pathway (Hazan et al., 1990) or, in the case of Y1248, may mediate transforming potential of ErbB2 (BenLevy et al., 1994) . Gefitinib showed some reduction of ErbB2 receptor phosphorylation on Y877 and Y1248 but had less effect on Y1221 than JNJ-28871063 and lapatinib while erlotinib had no effect, which may be explained by the slightly higher in vitro potency of gefitinib against the ErbB2 kinase. The Y877 residue couples ErbB2 to Src but does not modulate ErbB2 catalytic function or mitogenic activity . Erlotinib was less effective than the other compounds at inhibiting AKT phosphorylation on Ser473, which is required for mediating cell survival and blocking pro-apoptotic factors such as Bad, caspase-9 and forkhead (Burgering and Coffer, 1995) .
Surprisingly, erlotinib inhibited MAPK and PLCγ activation in BT474 cells although it showed no effect on ErbB2 receptor phosphorylation. These effects may be mediated through inhibition of EGFR transactivation although BT474 cells express low levels of EGFR. In EGFR overexpressing A431 cells, JNJ-28871063 inhibited EGFstimulated phosphorylation of all residues examined including the major autophosphorylation sites Y1068, Y1148
and Y1173 as well as Y845 and Y992 that serve as minor sites activating pathways leading to DNA synthesis and cell division (Biscardi et al., 1999) . The Y992 residue is a binding site for PLCγ (Emlet et al., 1997) while Y1068 serves as a binding site for the Grb2/SH2 domain and is essential for MAPK activation (Rojas et al., 1996) . The Y1173 site is important for EGF-mediated signal transduction and is also required for the enhanced tumorigenicity of the EGFRvIII mutant receptor (Su Huang et al., 1997) . JNJ-28871063 demonstrated activity equivalent to erlotinib at blocking receptor activation but was less effective than gefitinib and lapatinib. All compounds inhibited AKT phosphorylation equally but gefitinib was the only compound able to reduce MAP kinase phosphorylation to basal levels in this cell line. Interestingly, lapatinib was more active than erlotinib and equally as effective as gefitinib although the in vitro potency on purified EGFR kinase is quite similar for all the compounds examined.
A431 cells express very low levels of ErbB2 so the differences in activity may result from other factors such as cell permeability, stability of the compounds or off-target effects. JNJ-28871063 showed a similar activity profile to erlotinib in reducing EGFR phosphorylation in A431 cells but, as mentioned above, was more effective than erlotinib at reducing ErbB2 phosphorylation in BT474 cells.
JNJ-28871063 was highly efficacious in human tumor xenograft tumor models that overexpress EGFR or ErbB2. In particular, JNJ-28871063 potently inhibited the growth of the N87 gastric carcinoma that expresses high levels of This article has not been copyedited and formatted. The final version may differ from this version. ErbB2. In this model, JNJ-28871063 was more effective than the anti-ErbB2 antibody trastuzumab and the small molecule gefitinib (which targets the EGFR), and was equally effective compared with the pan-ErbB kinase inhibitor lapatinib. In xenograft models with the EGFR overexpressing cell line A431, JNJ-28871063 inhibited growth by >80%, and was more efficacious than lapatinib, but neither compound caused tumor regression that can be obtained with gefitinib.
Studies in nude mice indicated that JNJ-28871063 accumulates into tumor tissue at higher levels than found in plasma, giving this compound favorable pharmacokinetic properties for suppressing ErbB receptor phosphorylation in tumors. The ability to penetrate and accumulate into the brain in nude mice following oral administration and rats following i.v. administration (data not shown) also suggest that JNJ-28871063 may be efficacious against ErbB2 overexpressing intracranial metastases. In an N87 ErbB2 overexpressing intracranial model, JNJ-28871063 showed a statistically significant increase in survival over untreated mice following oral administration. The ability to penetrate into brain tissue could have therapeutic advantage as EGFR is often overexpressed in primary brain tumors and also in breast and non-small cell lung carcinomas that frequently metastasize to the brain (Wikstrand et al., 1995) . Furthermore, patients with ErbB2 overexpressing breast cancer frequently experience metastases to the brain (Kirsch and Hochberg, 2003) . These patients have an extremely poor prognosis and intracerebral tumors are often the cause of death. Autopsies revealed that 20-30% of patients who die of breast cancer have brain metastases (Grossi et al., 2003) . While there are preliminary reports of clinical activity against ErbB2 overexpressing brain metastases (Lin et al., 2006) , lapatinib was not able to penetrate into the brain of nude mice following oral administration. Whether lapatinib can cross the blood brain barrier (BBB) in humans has yet to be published.
However, the ability of a compound to cross the BBB in rodents does not predict for the human situation. In addition, the BBB is often compromised in cancer patients and the blood supply to intracranial tumors is abnormal with vasculature developing a tortuous and leaky conformation.
JNJ-28871063 is an orally available pan-ErbB inhibitor with a unique activity profile in cellular and animal models.
Its ability to penetrate into the brain may result in enhanced activity against ErbB overexpressing tumors that find refuge in the brain and provide a therapeutic benefit over many conventional therapies. Furthermore, small molecule kinase inhibitors may retain activity against tumors expressing the EGFRvIII mutant receptor that contains This article has not been copyedited and formatted. The final version may differ from this version. p.o. = oral gavage, i.p. = intraperitoneal. c qd = every day, biw = twice a week. d TGI (tumor growth inhibition) was calculated as the difference between the change in control and drug treated tumor volumes (T/C) on the last day of the study. e Statistical significance was evaluated by comparing the mean tumor size of control groups to drug treated groups using a two tailed Students t test.
